Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Replimune Group Inc ha un obiettivo di prezzo di consenso pari a $18.6, stabilito in base alle ultime valutazioni degli analisti di 12. Le ultime 3 valutazioni degli analisti sono state rilasciate da JP Morgan, Leerink Partners y Wedbush il octubre 20, 2025. Con un obiettivo di prezzo medio di $14 tra le JP Morgan, Leerink Partners y Wedbush, c'è un implicito 71.99% upside per Replimune Group Inc da queste valutazioni degli analisti.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/20/2025 | 35.14% | JP Morgan | → $11 | Upgrade | Underweight → Neutral | |||
10/20/2025 | 59.71% | Leerink Partners | $3 → $13 | Upgrade | Market Perform → Outperform | |||
10/20/2025 | 121.13% | Wedbush | $4 → $18 | Upgrade | Neutral → Outperform | |||
09/19/2025 | — | JP Morgan | — | Downgrade | Neutral → Underweight | |||
09/08/2025 | — | HC Wainwright & Co. | — | Reiterates | Neutral → Neutral | |||
07/30/2025 | — | Cantor Fitzgerald | — | Upgrade | Neutral → Overweight | |||
07/23/2025 | -75.43% | BMO Capital | $27 → $2 | Downgrade | Outperform → Underperform | |||
07/23/2025 | -63.14% | Barclays | $17 → $3 | Downgrade | Overweight → Equal-Weight | |||
07/23/2025 | — | HC Wainwright & Co. | — | Downgrade | Buy → Neutral | |||
07/22/2025 | -63.14% | Leerink Partners | $21 → $3 | Downgrade | Outperform → Market Perform | |||
07/22/2025 | 10.57% | JP Morgan | $19 → $9 | Downgrade | Overweight → Neutral | |||
07/22/2025 | -26.29% | Jefferies | $31 → $6 | Maintains | Buy | |||
07/22/2025 | -50.86% | Wedbush | $19 → $4 | Downgrade | Outperform → Neutral | |||
07/16/2025 | 133.42% | JP Morgan | $16 → $19 | Maintains | Overweight | |||
07/03/2025 | 170.27% | HC Wainwright & Co. | $22 → $22 | Reiterates | Buy → Buy | |||
06/20/2025 | — | Cantor Fitzgerald | — | Initiates | → Overweight | |||
06/02/2025 | 170.27% | Piper Sandler | $14 → $22 | Maintains | Overweight | |||
02/26/2025 | 121.13% | JP Morgan | $16 → $18 | Maintains | Overweight | |||
02/13/2025 | 170.27% | HC Wainwright & Co. | $21 → $22 | Maintains | Buy | |||
01/22/2025 | 231.7% | BMO Capital | $18 → $27 | Maintains | Outperform | |||
01/22/2025 | 157.99% | HC Wainwright & Co. | $17 → $21 | Maintains | Buy | |||
12/04/2024 | 133.42% | Jefferies | $16 → $19 | Maintains | Buy | |||
11/22/2024 | 121.13% | BMO Capital | $14 → $18 | Maintains | Outperform | |||
11/22/2024 | 108.85% | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
11/12/2024 | 108.85% | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
09/24/2024 | 108.85% | JP Morgan | $14 → $17 | Maintains | Overweight | |||
09/16/2024 | 108.85% | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
09/10/2024 | 108.85% | HC Wainwright & Co. | $17 → $17 | Reiterates | Buy → Buy | |||
08/27/2024 | 108.85% | Roth MKM | → $17 | Initiates | → Buy | |||
08/13/2024 | 71.99% | JP Morgan | $17 → $14 | Maintains | Overweight | |||
06/07/2024 | 108.85% | Barclays | $13 → $17 | Maintains | Overweight | |||
06/07/2024 | 108.85% | HC Wainwright & Co. | $12 → $17 | Maintains | Buy | |||
12/06/2023 | 59.71% | Barclays | $50 → $13 | Maintains | Overweight | |||
11/13/2023 | 489.68% | HC Wainwright & Co. | $50 → $48 | Maintains | Buy | |||
11/08/2023 | 538.82% | Wedbush | → $52 | Reiterates | Outperform → Outperform | |||
08/07/2023 | 514.25% | HC Wainwright & Co. | $51 → $50 | Maintains | Buy | |||
08/01/2023 | 526.54% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
06/15/2023 | 514.25% | JP Morgan | $38 → $50 | Maintains | Overweight | |||
06/08/2023 | 526.54% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
06/07/2023 | 538.82% | Wedbush | → $52 | Reiterates | Outperform → Outperform | |||
06/07/2023 | 637.1% | EF Hutton | → $60 | Reiterates | Buy → Buy | |||
06/05/2023 | 526.54% | HC Wainwright & Co. | $50 → $51 | Maintains | Buy | |||
06/05/2023 | 637.1% | EF Hutton | → $60 | Reiterates | Buy → Buy | |||
05/26/2023 | 637.1% | EF Hutton | → $60 | Reiterates | Buy → Buy | |||
05/22/2023 | 538.82% | Wedbush | → $52 | Reiterates | Outperform → Outperform | |||
04/17/2023 | 440.54% | Piper Sandler | → $44 | Assumes | → Overweight | |||
02/10/2023 | 514.25% | HC Wainwright & Co. | $48 → $50 | Reiterates | → Buy | |||
01/05/2023 | 637.1% | EF Hutton | → $60 | Initiates | → Buy | |||
12/12/2022 | 759.95% | BMO Capital | $40 → $70 | Maintains | Outperform | |||
12/07/2022 | 317.69% | SVB Leerink | $30 → $34 | Maintains | Outperform | |||
11/04/2022 | 489.68% | HC Wainwright & Co. | $60 → $48 | Maintains | Buy |
El último precio objetivo de Replimune Group (NASDAQ:REPL) fue comunicado por JP Morgan el octubre 20, 2025. La firma de analistas fijó un precio objetivo para $11.00 que espera REPL a rise dentro de 12 meses (un posible 35.14% upside). 25 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Replimune Group (NASDAQ:REPL) fue proporcionada por JP Morgan, y Replimune Group mejorado su neutral calificación.
La última revisión al alza de Replimune Group Inc se produjo en octubre 20, 2025, cuando JP Morgan elevó su precio objetivo a $11. JP Morgan anteriormente tenía an underweight para Replimune Group Inc.
La última revisión a la baja de Replimune Group Inc se produjo en septiembre 19, 2025, cuando JP Morgan cambió su precio objetivo de N/A a N/A para Replimune Group Inc.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Replimune Group, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Replimune Group se registró el octubre 20, 2025, por lo que la próxima calificación estará disponible en torno al octubre 20, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Replimune Group (REPL) fue un mejorado con un precio objetivo de $0.00 a $11.00. El precio actual al que cotiza Replimune Group (REPL) es de $8.14, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.